Moreover, the inhibition of Fli-1 in two lupus mouse strains (MRL/lpr and NZM2410) significantly attenuated lupus disease severity, as evidenced by prolonged survival [42,50], decreased pathological damage and infiltrating inflammatory cells in kidney [30], reduced total B cell and activated B cell populations in the spleens and autoantibody production [22], and lessened pathogenicity of T cells with TCR-specific activation and glycosphingolipid levels [21,31]. Here, FLI1 is linked to systemic lupus erythematosus.